MULTIPLE ELECTROLYTE ADDITIVE LIQ FORMULA 1 4.07 G / 100 ML
MAGNESIUM CHLORIDE : 4.07 G / 100 ML POTASSIUM CHLORIDE : 7.46 G / 100 ML SODIUM ACETATE : 13.6 G / 100 ML CALCIUM CHLORIDE : 1.84 G / 100 ML SODIUM CHLORIDE : 7.31 G / 100 ML · DIN 00809551 · BAXTER CORPORATION
Health Canada status: CANCELLED POST MARKET
What is MULTIPLE ELECTROLYTE ADDITIVE LIQ FORMULA 1?
MULTIPLE ELECTROLYTE ADDITIVE LIQ FORMULA 1 4.07 G / 100 ML contains MAGNESIUM CHLORIDE : 4.07 G / 100 ML POTASSIUM CHLORIDE : 7.46 G / 100 ML SODIUM ACETATE : 13.6 G / 100 ML CALCIUM CHLORIDE : 1.84 G / 100 ML SODIUM CHLORIDE : 7.31 G / 100 ML. It is listed in the Health Canada Drug Product Database under DIN 00809551, held by BAXTER CORPORATION, supplied as LIQUID for INTRAVENOUS administration. Health Canada currently lists it as cancelled post market, status dated 07-Oct-2015. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
Product details and regulatory record
| DIN | 00809551 |
|---|---|
| Brand name | MULTIPLE ELECTROLYTE ADDITIVE LIQ FORMULA 1 |
| Generic / active ingredient | MAGNESIUM CHLORIDE : 4.07 G / 100 ML POTASSIUM CHLORIDE : 7.46 G / 100 ML SODIUM ACETATE : 13.6 G / 100 ML CALCIUM CHLORIDE : 1.84 G / 100 ML SODIUM CHLORIDE : 7.31 G / 100 ML |
| Manufacturer | BAXTER CORPORATION |
| Strength | 4.07 G / 100 ML |
| Dosage form | LIQUID |
| Route of administration | INTRAVENOUS |
| Schedule | Ethical |
| ATC code | B05BB01 ELECTROLYTES |
| AHFS class | 40:12.00 |
| Biosimilar | No |
| Health Canada status | CANCELLED POST MARKET |
| Status date | 07-Oct-2015 |
| Original market date | 1989-12-31 00:00:00 |
What can be used instead?
Other Canadian products sharing ATC code B05BB01 ELECTROLYTES. 10 of 20 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| (20MMOL/L) POTASSIUM CHLORIDE IN 0.9% SODIUM CHLORIDE INJECTION USP | 150 MG / 100 ML | SOLUTION | BAXTER CORPORATION | MARKETED | DIN 00786209 |
| (40 MMOL/L) POTASSIUM CHLORIDE IN 0.9% SODIUM CHLORIDE INJECTION USP | 300 MG / 100 ML | LIQUID | BAXTER CORPORATION | MARKETED | DIN 00786217 |
| ISOLYTE S (MULTI-ELECTROLYTE INJECTION) | 530 MG / 100 ML | SOLUTION | B. BRAUN MEDICAL INC | MARKETED | DIN 01931628 |
| ISOLYTE S PH 7.4 (MULTI-ELECTROLYTE INJECTION) | 820 MCG / 100 ML | SOLUTION | B. BRAUN MEDICAL INC | MARKETED | DIN 01931679 |
| LACTATED RINGER'S INJECTION | 3.1 MG | SOLUTION | ICU MEDICAL CANADA INC | MARKETED | DIN 00039470 |
| LACTATED RINGER'S INJECTION USP | 20 MG / 100 ML | SOLUTION | B. BRAUN MEDICAL INC | MARKETED | DIN 01931636 |
| LACTATED RINGER'S INJECTION, USP | 310 MG / 100 ML | SOLUTION | BAXTER CORPORATION | MARKETED | DIN 00061085 |
| PLASMA-LYTE A INJECTION | 30 MG / 100 ML | SOLUTION | BAXTER CORPORATION | MARKETED | DIN 02339358 |
| POTASSIUM CHLORIDE IN LACTATED RINGER'S INJECTION | 20 MG / 100 ML | LIQUID | BAXTER CORPORATION | MARKETED | DIN 02243421 |
| POTASSIUM CHLORIDE IN SODIUM CHLORIDE INJECTION USP | 450 MG / 100 ML | SOLUTION | BAXTER CORPORATION | MARKETED | DIN 02269414 |
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Request a quote for MULTIPLE ELECTROLYTE ADDITIVE LIQ FORMULA 1
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.